CHINA PHARMA HOLDINGS, INC. Deferred Federal Income Tax Expense (Benefit)
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Deferred Federal Income Tax Expense (Benefit) of $77.04 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-12-28.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2015-12-28
- CHINA PHARMA HOLDINGS, INC. deferred federal income tax expense (benefit) for the quarter ending 2014-12-31 was $19.28K, a 99.12% decline year-over-year.
- CHINA PHARMA HOLDINGS, INC. deferred federal income tax expense (benefit) for the quarter ending 2014-09-30 was $19.21K.
- CHINA PHARMA HOLDINGS, INC. deferred federal income tax expense (benefit) for the quarter ending 2014-06-30 was $19.20K.
- CHINA PHARMA HOLDINGS, INC. deferred federal income tax expense (benefit) for the quarter ending 2014-03-31 was $19.35K.
- CHINA PHARMA HOLDINGS, INC. deferred federal income tax expense (benefit) for fiscal 2014 was $77.04K, a 92.74% decline from fiscal 2013.
- CHINA PHARMA HOLDINGS, INC. deferred federal income tax expense (benefit) for fiscal 2013 was $1.06M.
- CHINA PHARMA HOLDINGS, INC. deferred federal income tax expense (benefit) for fiscal 2012 was -$430.25K.
- CHINA PHARMA HOLDINGS, INC. deferred federal income tax expense (benefit) for fiscal 2011 was -$16.21K.
| Period end | Deferred Federal Income Tax Expense (Benefit) 3 month | Deferred Federal Income Tax Expense (Benefit) 6 month | Deferred Federal Income Tax Expense (Benefit) 9 month | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2014-12-31 | $19.28K derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-28 | $38.50K derived: sum of 2 quarters · filed 2015-12-28 | $57.70K derived: sum of 3 quarters · filed 2015-12-28 | $77.04K 10-K · filed 2015-12-28 | |
| 2014-09-30 | $19.21K 10-Q · filed 2014-11-14 | $38.41K derived: sum of 2 quarters · filed 2014-11-14 | $57.76K 10-Q · filed 2014-11-14 | $2.25M derived: sum of 4 quarters · filed 2015-12-28 | |
| 2014-06-30 | $19.20K 10-Q · filed 2014-08-14 | $38.54K 10-Q · filed 2014-08-14 | $2.23M derived: sum of 3 quarters · filed 2015-12-28 | $1.76M derived: sum of 4 quarters · filed 2015-12-28 | |
| 2014-03-31 | $19.35K 10-Q · filed 2014-05-15 | $2.21M derived: sum of 2 quarters · filed 2015-12-28 | $1.74M derived: sum of 3 quarters · filed 2015-12-28 | $1.35M derived: sum of 4 quarters · filed 2015-12-28 | |
| 2013-12-31 | $2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-28 | $1.72M derived: sum of 2 quarters · filed 2015-12-28 | $1.33M derived: sum of 3 quarters · filed 2015-12-28 | $1.06M 10-K · filed 2015-12-28 | |
| 2013-09-30 | -$472.51K 10-Q · filed 2014-11-14 | -$860.50K derived: sum of 2 quarters · filed 2014-11-14 | -$1.13M 10-Q · filed 2014-11-14 | -$1.49M derived: sum of 4 quarters · filed 2014-11-14 | |
| 2013-06-30 | -$387.98K 10-Q · filed 2014-08-14 | -$656.99K 10-Q · filed 2014-08-14 | -$1.02M derived: sum of 3 quarters · filed 2014-08-14 | -$1.03M derived: sum of 4 quarters · filed 2014-08-14 | |
| 2013-03-31 | -$269.01K 10-Q · filed 2014-05-15 | -$631.66K derived: sum of 2 quarters · filed 2014-05-15 | -$643.63K derived: sum of 3 quarters · filed 2014-05-15 | -$664.95K derived: sum of 4 quarters · filed 2014-05-15 | |
| 2012-12-31 | -$362.65K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-20 | -$374.62K derived: sum of 2 quarters · filed 2014-03-20 | -$395.94K derived: sum of 3 quarters · filed 2014-03-20 | -$430.25K 10-K · filed 2014-03-20 | |
| 2012-09-30 | -$11.97K 10-Q · filed 2013-11-14 | -$33.29K derived: sum of 2 quarters · filed 2013-11-14 | -$67.60K 10-Q · filed 2013-11-14 | ||
| 2012-06-30 | -$21.32K 10-Q · filed 2013-08-14 | -$55.63K 10-Q · filed 2013-08-14 | |||
| 2012-03-31 | -$34.31K 10-Q · filed 2013-05-14 | ||||
| 2011-12-31 | -$16.21K 10-K · filed 2013-03-14 | $37.28K 10-K · filed 2012-03-14 | |||
| 2010-12-31 | -$123.18K 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |